Skip to main content
SpringerLink
Log in

Systemic Chemotherapy for Upper Tract Urothelial Cancer

  • Chapter
Upper Urinary Tract Urothelial Carcinoma

Abstract

The use of chemotherapy for upper tract urothelial cancer (UC) varies widely geographically and institutionally. There have been no large scale prospective studies to support use of perioperative chemotherapy for curative intent for upper tract UC. Based upon level 1 evidence supporting the use of neoadjuvant cisplatin based chemotherapy prior to radical cystectomy, many centers will extrapolate this data and use neoadjuvant cisplatin chemotherapy prior to nephroureterectomy. Others favor adjuvant chemotherapy based on pathologic stage following nephroureterectomy, or offer no chemotherapy at all. Loss of renal unit, and often vital renal function, can preclude the safe use of cisplatin in the post nephrectomy setting. The current evidence for use of perioperative chemotherapy for upper tract urothelial cancer and eligibility for cisplatin, the most active chemotherapeutic in urothelial cancer, will be reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly W, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014;32(5):637–44.

    Article  PubMed  Google Scholar 

  2. Bamias A, Deliveliotis C, Fountzilas G, Gika D, Anagnostopoulos A, Zorzou MP, Kastritis E, Constantinides C, Kosmidis P, Dimopoulos MA. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22(11):2150–4.

    Article  CAS  PubMed  Google Scholar 

  3. Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin M, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense Methotrexate, vinblastine, doxorubicin, and cisplatin with Pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32(18):1889–94.

    Article  CAS  PubMed  Google Scholar 

  4. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–8.

    Article  PubMed  Google Scholar 

  5. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, White RWD, Sarosdy MF, Wood Jr DP, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.

    Article  CAS  PubMed  Google Scholar 

  6. Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol. 2009;182(3):900–6.

    Article  PubMed  Google Scholar 

  7. Hoffman-Censits JH, Trabulsi EJ, Chen DYT, Kutikov A, Lin J, Viterbo R, Hudes GR, Healy KA, Hubosky S, Wong Y, Kilpatrick D, Adair B, Cione C, Plimack ER. Neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in patients with high-grade upper-tract urothelial carcinoma. ASCO Meeting Abstr. 2014;32(4 Suppl):326.

    Google Scholar 

  8. Igawa M, Urakami S, Shiina H, Kishi H, Himeno Y, Ishibe T, Kadena H, Usui T. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int. 1995;55(2):74–7.

    Article  CAS  PubMed  Google Scholar 

  9. Kaag M, Trost L, Thompson RH, Favaretto R, Elliott V, Shariat SF, Maschino A, Vertosick E, Raman JD, Dalbagni G. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2014;114(5):674–9.

    Article  CAS  PubMed  Google Scholar 

  10. Kawashima A, Nakai Y, NAKAYAMA M, Ujike T, Tanigawa G, Ono Y, Kamoto A, TAKADA T, Yamaguchi Y, Takayama H, Nishimura K, Nonomura N, Tsujimura A. The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study. World J Urol. 2012;30(5):701–6.

    Article  CAS  PubMed  Google Scholar 

  11. Kitamura H, Igarashi M, Tanaka T, Shindo T, Masumori N, Tamakawa M, Kawaai Y, Tsukamoto T. A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy. Jpn J Clin Oncol. 2012;42(12):1192–6.

    Article  PubMed  Google Scholar 

  12. Lane BR, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, Dreicer R, Hansel DE, Stephenson AJ. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer. 2010;116(12):2967–73.

    Article  PubMed  Google Scholar 

  13. Lee SE, Byun SS, Park YH, Chang IH, Kim YJ, Hong SK. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int. 2006;77(1):22–6.

    Article  CAS  PubMed  Google Scholar 

  14. Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI, Black PC, Fajkovic H, Seitz C, Remzi M, Nyirády P, Rouprêt M, Margulis V, Lotan Y, de Martino M, Hofbauer SL, Karakiewic PI, Briganti A, Novara G, Shariat SF, Klatte T. (2015), The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. BJU International. 2014;115:1–7 doi: 10.1111/bju.12801.

    Google Scholar 

  15. Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010;116(13):3127–34.

    Article  PubMed  Google Scholar 

  16. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DYT, Lallas CD, Wong Y, Lin J, Kutikov A, DOTAN E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32(18):1895–901.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014;120(12):1794–9.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology. 2011;78(1):61–7.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Raman JD, Ng CK, Shariat SF, Margulis V, Montorsi F, Karakiewicz P, Upper-Tract Urothelial Carcinoma Collaboration. Outcomes for patients with pT0 disease after radical nephroureterectomy for upper-tract urothelial carcinoma. BJU International. 2009;103(1):3–4.

    Article  PubMed  Google Scholar 

  20. Shao IH, Lin YH, Hou CP, Juang HH, Chen CL, Chang PL, Tsui KH. Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. Drug Des Devel Ther. 2014;8:1985–90.

    PubMed Central  PubMed  Google Scholar 

  21. Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high-risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience. J Urol. 2015;193(4):1122–8.

    Article  CAS  PubMed  Google Scholar 

  22. Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the M. D. Anderson Cancer Center. ASCO Meeting Abstr. 2012;30(5 Suppl):261.

    Google Scholar 

  23. Soga N, Arima K, Sugimura Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol Off J Jpn Urol Assoc. 2008;15(9):800–3.

    CAS  Google Scholar 

  24. Sternberg CN, De Mulder PHM, Schornagel JH, Théodore C, Fossa SD, Van Oosterom AT, Witjes F, Spina M, Van Groeningen CJ, de Balincourt C, Collette L, For the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high–dose-intensity Methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol. 2001;19(10):2638–46.

    CAS  PubMed  Google Scholar 

  25. Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos MA, Papadimitriou CA, Bamias A, Pignot G, Nouhaud FX, Hurel S, Guy L, Bigot P, Roumiguie M, Roupret M, French Collaborative National Database on UUT-UCC. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer. 2011;117(24):5500–8.

    Article  PubMed  Google Scholar 

  26. Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.

    PubMed  Google Scholar 

  27. Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, Roupret M, Pycha A, Scherr DS, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Shariat SF, UTUC Collaboration. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU International. 2013;112(4):453–61.

    Article  CAS  PubMed  Google Scholar 

  28. Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf J, Bell D, Fradet Y, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Kassouf W. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol Semin Orig Invest. 2014;32(1):31.e17–24.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, 19107, USA

    Jean Hoffman-Censits MD

Authors
  1. Jean Hoffman-Censits MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean Hoffman-Censits MD .

Editor information

Editors and Affiliations

  1. Lenox Hill Hospital, Department of Urology, New York Medical College, Valhala, New York, New York, New York, USA

    Michael Grasso III

  2. Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

    Demetrius H. Bagley

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hoffman-Censits, J. (2015). Systemic Chemotherapy for Upper Tract Urothelial Cancer. In: Grasso III, M., Bagley, D. (eds) Upper Urinary Tract Urothelial Carcinoma. Springer, Cham. https://doi.org/10.1007/978-3-319-13869-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-13869-5_8

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-13868-8

  • Online ISBN: 978-3-319-13869-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation